Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan granted UK approval for Botox as migraine treatment

Allergan granted UK approval for Botox as migraine treatment

12th July 2010

Allergan has been granted the backing of UK regulators for the sale of its treatment Botox as a therapy for chronic migraine sufferers.

The Medicines and Healthcare Products Regulatory Agency has extended the licence of the product for the prophylaxis of headaches in adults who have chronic migraine problems, representing the first licensing of Botox for this application worldwide.

It granted approval for the new indication based on positive findings from a phase III clinical trial, which showed the efficacy of Botox as a preventative measure against headaches.

Dr Scott Whitcup, Allergan’s executive vice-president of research and development and chief scientific officer, said the authorisation represents “an evolution in medical care” for migraine patients.

He added: “There is an unmet need for effective and well-tolerated therapies specifically designed and studied for the prophylaxis of headache in chronic migraine.”

Allergan announced earlier this month that it has appointed Douglas Ingram as the new chief of its Europe, Africa and Middle East business division, with the executive set to take up the role next month.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.